Yesterday, the CEO of Melinta Therapeutics Inc (MLNT), John Johnson, sold shares of MLNT for $72.41K.
See today’s analyst top recommended stocks >>
Based on Melinta Therapeutics Inc’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $14.08 million and GAAP net loss of $26.53 million. In comparison, last year the company earned revenue of $12.02 million and had a GAAP net loss of $55.78 million. Currently, Melinta Therapeutics Inc has an average volume of 1.93M.
Based on 6 analyst ratings, the analyst consensus is Hold with an average price target of $14.00, reflecting a 109.3% upside.
John Johnson’s trades have generated a 129.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Melinta Therapeutics, Inc. operates as a commercial-stage pharmaceutical company which engages in developing and commercializing anti-infective s for the hospital and selected non-hospital or communities. It markets antibiotics including Baxdela, Vabomere, Orbactiv, and Minocin for injections.
